MedTrace Logo

Ground-Breaking Electroporation-based Intervention for PERSistent Atrial Fibrillation Treatment (BEAT PERS-AF)

NCT05418725 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2025-06-17

No results posted yet for this study

Summary

BEAT AF is a randomized controlled trial aiming to assess the efficacy and the safety of pulsed field energy in persistent AF ablation

Conditions

Interventions

DEVICE

PVI and Linear lesion using PEF

PVI and Linear lesion using PEF

DEVICE

PVI and Linear lesion using CFRF

PVI and Linear lesion using CFRF

Sponsors & Collaborators

  • Horizon 2020 - European Commission

    collaborator OTHER

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Pierre Jais, MD, PhD · University Hospital, Bordeaux

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-04
Primary Completion
2025-05-28
Completion
2025-05-28
FDA Device
Yes

Countries

  • Austria
  • Belgium
  • Czechia
  • France
  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05418725 on ClinicalTrials.gov